Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality

Clinical and Experimental Immunology

Volumn 174, Issue 3, 2013, Pages 441-448

  Frostegard A G ^a   Hua, X ^a   Su, J ^a   Carrero, J J ^a   Heimburger O ^a   Barany P ^a   Stenvinkel, P ^a   Frostegard J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antibodies; Atherosclerosis; Cardiolipin; Cardiovascular disease; Haemodialysis; Inflammation

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN ANTIBODY; INTERLEUKIN 6; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; BODY MASS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING;

ANTIBODIES; ATHEROSCLEROSIS; CARDIOLIPIN; CARDIOVASCULAR DISEASE; HAEMODIALYSIS; INFLAMMATION;

AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ATHEROSCLEROSIS; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CARDIOLIPINS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK;

EID: 84886310335     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12181     Document Type: Article

References (37)

1. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268:456-467.
2. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3:505-521.
3. Frostegard J, Ulfgren AK, Nyberg P etal. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145:33-43.
4. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485.
5. Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005; 23:72-78.
6. Zalewski A, Nelson JJ, Hegg L, Macphee C. Lp-PLA2: a new kid on the block. Clin Chem 2006; 52:1645-1650.
7. Caidahl K, Hartford M, Karlsson T etal. IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes. Int J Cardiol 2012; 167:464-469.
8. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol 2010; 134:47-54.
9. Fiskesund R, Stegmayr B, Hallmans G etal. Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. Stroke 2010; 41:607-612.
10. de Faire U, Su J, Hua X etal. Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. J Autoimmun 2010; 34:73-79.
11. Sjoberg BG, Su J, Dahlbom I etal. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 2009; 203:528-532.
12. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982; 156:1177-1185.
13. Schlame M. Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J Lipid Res 2008; 49:1607-1620.
14. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25:1776-1785.
15. Su J, Hua X, Vikstrom M etal. Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study. BMC Cardiovasc Disord 2013; 13:1.
16. Carrero JJ, Qureshi AR, Axelsson J etal. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007; 85:695-701.
17. Carrero JJ, Hua X, Stenvinkel P etal. Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. Nephrol Dial Transplant 2009; 24:3454-3460.
18. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17:1085-1092.
19. Martin W, Hoffmeister M, Rotte C, Henze K. An overview of endosymbiotic models for the origins of eukaryotes, their ATP-producing organelles (mitochondria and hydrogenosomes), and their heterotrophic lifestyle. Biol Chem 2001; 382:1521-1539.
20. Horkko S, Miller E, Dudl E etal. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98:815-825.
21. Deguchi H, Fernandez JA, Hackeng TM, Banka CL, Griffin JH. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci USA 2000; 97:1743-1748.
22. Dashti M, Kulik W, Hoek F, Veerman EC, Peppelenbosch MP, Rezaee F. A phospholipidomic analysis of all defined human plasma lipoproteins. Sci Rep 2012; 1:139.
23. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87:904-908.
24. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb 1992; 12:461-467.
25. Berliner JA, Territo MC, Sevanian A etal. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 1990; 85:1260-1266.
26. Frostegard J, Huang YH, Ronnelid J, Schafer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol 1997; 17:963-968.
27. Huang YH, Schafer-Elinder L, Wu R, Claesson HE, Frostegard J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol 1999; 116:326-331.
28. Ray NB, Durairaj L, Chen BB etal. Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia. Nat Med 2010; 16:1120-1127.
29. Tyurina YY, Tyurin VA, Kapralova VI etal. Oxidative lipidomics of gamma-radiation-induced lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Radiat Res 2011; 175:610-621.
30. Tyurina YY, Tyurin VA, Kaynar AM etal. Oxidative lipidomics of hyperoxic acute lung injury: mass spectrometric characterization of cardiolipin and phosphatidylserine peroxidation. Am J Physiol Lung Cell Mol Physiol 2010; 299:L73-85.
31. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002; 22:1370-1380.
32. Kagan VE, Tyurin VA, Jiang J etal. Cytochrome C acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 2005; 1:223-232.
33. Chen Y, Khanna S, Goodyear CS etal. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol 2009; 183:1346-1359.
34. Svenungsson E, Jensen-Urstad K, Heimburger M etal. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104:1887-1893.
35. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164:659-663.
36. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012; 38:322-327.
37. Horkko S, Miller E, Branch DW, Palinski W, Witztum JL. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci USA 1997; 94:10356-10361.